Simple Summary Venetoclax has proven to be a promising therapy for newly diagnosed,
relapsed and refractory AML patients ineligible for induction chemotherapy. Current ongoing …

Abstract Azacitidine+ venetoclax, decitabine+ venetoclax, and low-dose cytarabine+
venetoclax are now standard treatments for newly diagnosed older or unfit patients with …

Acute myeloid leukemia (AML) is a highly aggressive hematological malignancy with
complex heterogenous genetic and biological nature. Thus, prognostic prediction and …

Acute myeloid leukemia (AML) is an aggressive malignancy characterized by clonal
proliferation of neoplastic immature precursor cells. AML impacts older adults and has a …

Acute myeloid leukemia (AML) is characterized by attenuation of lineage differentiation
trajectories that results in impaired hematopoiesis and enhanced self-renewal. To date …

Background Acute myeloid leukemia, the most common acute leukemia in adults, has a poor
overall survival. Studies have suggested that certain socioeconomic factors such as living in …

Purpose: We aimed to describe RAS mutations in gynecologic cancers as they relate to
clinicopathologic and genomic features, survival, and therapeutic implications. Experimental …

Somatic mutations in the isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) genes occur in
up to 20% of patients with acute myeloid leukemia (AML). 1, 2 Ivosidenib (AG-120) and …

Генетические нарушения, детектируемые методами кариотипирования,
флуоресцентной гибридизации in situ (FISH), а также различными вариантами ПЦР и …

Acute myeloid leukaemia (AML) is a clinically heterogeneous disease driven by somatic
mutations and chromosomal abnormalities. TET2 mutations occur in 7%-23% of AML, with …